martes, 2 de junio de 2020

Experimental Hematology & Oncology | Articles

Experimental Hematology & Oncology | Articles

EHO Logo

  1. Angiogenesis and activation of the epidermal growth factor (EGFR) pathway play an essential role in tumor proliferation and metastasis. Targeting angiogenesis or EGFR alone does not yield adequate tumor contro...
    Authors:Vivek Subbiah, Ecaterina Ileana Dumbrava, Yunfang Jiang, Kyaw Z. Thein, Aung Naing, David S. Hong, Siqing Fu, Sarina A. Piha-Paul, Apostolia M. Tsimberidou, Filip Janku, Funda Meric-Bernstam, Razelle Kurzrock and Gerald Falchook
    Citation:Experimental Hematology & Oncology 2020 9:7
    Content type:Research
     
    Published on: 

  2. The efficacy and safety of rituximab (RTX) on hemolytic anemia (HA) is unknown. Therefore we retrospectively analyze the efficacy and safety of RTX in autoimmune hemolytic anemia (AIHA) and microangiopathic he...
    Authors:Shih-Hsuan Chao, Yuh-Lih Chang, Jiin-Cherng Yen, Hsien-Tzung Liao, Tsai-Hung Wu, Chia-Li Yu, Chang-Youh Tsai and Yueh-Ching Chou
    Citation:Experimental Hematology & Oncology 2020 9:6
    Content type:Research
     
    Published on: 

  3. The high-risk refractory and/or relapsed (R/R) childhood acute leukemia prognosis is poor, and allogeneic stem cell transplantation (allo-HSCT) is the most prudent treatment modality. However, there are limite...
    Authors:Binglei Zhang, Jian Zhou, Fengkuan Yu, Tianxin Lv, Baijun Fang, Dandan Fan, Zhenyu Ji and Yongping Song
    Citation:Experimental Hematology & Oncology 2020 9:5
    Content type:Research
     
    Published on: 

  4. Acute myeloid leukemia (AML) is a genetically heterogeneous clonal malignancy characterized by recurrent gene mutations. Genomic heterogeneity, patients’ individual variability, and recurrent gene mutations ar...
    Authors:Jifeng Yu, Yingmei Li, Danfeng Zhang, Dingming Wan and Zhongxing Jiang
    Citation:Experimental Hematology & Oncology 2020 9:4
    Content type:Review
     
    Published on: 

  5. The DNA hypomethylating agents (HMAs) decitabine and azacitidine have been widely used in the management of elderly patients with acute myeloid leukemia (AML). However, no direct clinical trials have been carr...
    Authors:Bingbing Wen, Weiwen You, Sitian Yang and Xin Du
    Citation:Experimental Hematology & Oncology 2020 9:3
    Content type:Review
     
    Published on: 

  6. In this study, we retrospectively summarized the differences of molecular gene mutations between MDS and AML patients, as well as the young and older age groups of MDS and AML patients. We also analyzed the re...
    Authors:Jifeng Yu, Yingmei Li, Tao Li, Yafei Li, Haizhou Xing, Hui Sun, Ling Sun, Dingming Wan, Yanfang Liu, Xinsheng Xie and Zhongxing Jiang
    Citation:Experimental Hematology & Oncology 2020 9:2
    Content type:Research
     
    Published on: 

  7. Evasion from programmed cell death is a hallmark of cancer and can be achieved in cancer cells by overexpression of inhibitor of apoptosis proteins (IAPs). Second mitochondria-derived activator of caspases (SM...
    Authors:Brianna M. Craver, Thanh Kim Nguyen, Jenny Nguyen, Hellen Nguyen, Christy Huynh, Sarah J. Morse and Angela G. Fleischman
    Citation:Experimental Hematology & Oncology 2020 9:1
    Content type:Research
     
    Published on: 

  8. Cancer cells with strong immunogenicity are susceptible for elimination by cancer immunoediting, while the subpopulations with weak immunogenicity survive. As a result, a subset of cancer cells evade the immun...
    Authors:Ming Yi, Bing Dong, Qian Chu and Kongming Wu
    Citation:Experimental Hematology & Oncology 2019 8:32
    Content type:Editorial
     
    Published on: 
    The Article to this article has been published in Nature 2019 567:1032

  9. Considerable progress has been made in cancer therapeutics recently with targeted strategies that are efficacious and less toxic. Immunotherapy and chimeric antigen receptor (CAR) T-cells are increasingly bein...
    Authors:Muhammad Bilal Abid, Nirav N. Shah, Theresa C. Maatman and Parameswaran N. Hari
    Citation:Experimental Hematology & Oncology 2019 8:31
    Content type:Review
     
    Published on: 

  10. Medulloblastoma is the most frequently occurring malignant brain tumor in children. Current treatment strategies for medulloblastoma include aggressive surgery, cranio-spinal irradiation and adjuvant chemother...
    Authors:Shanshan Zhang, Zhaojian Gong, Peter O. Oladimeji, Duane G. Currier, Qipan Deng, Ming Liu, Taosheng Chen and Yong Li
    Citation:Experimental Hematology & Oncology 2019 8:30
    Content type:Research
     
    Published on: 

  11. DNA damage repair deficiency leads to the increased risk of genome instability and oncogenic transformation. In the meanwhile, this deficiency could be exploited for cancer treatment by inducing excessive geno...
    Authors:Ming Yi, Bing Dong, Shuang Qin, Qian Chu, Kongming Wu and Suxia Luo
    Citation:Experimental Hematology & Oncology 2019 8:29
    Content type:Review
     
    Published on: 

  12. Although complete remission rate of B cell acute lymphoblastic leukemia (B-ALL) has improved significantly over the past few decades, patients with relapsed/refractory ALL still have dismal outcome. Tyrosine k...
    Authors:Juanjuan Zhao, Yongping Song and Delong Liu
    Citation:Experimental Hematology & Oncology 2019 8:28
    Content type:Review
     
    Published on: 

  13. The use of chimeric antigen receptor (CAR) T cell technology as a therapeutic strategy for the treatment blood-born human cancers has delivered outstanding clinical efficacy. However, this treatment modality c...
    Authors:Bill X. Wu, No-Joon Song, Brian P. Riesenberg and Zihai Li
    Citation:Experimental Hematology & Oncology 2019 8:27
    Content type:Editorial
     
    Published on: 

  14. Recently, a series of clinical trials showed that combination of anti-programmed cell death-1 (α-PD-1) and anti-cytotoxic T-lymphocyte-associated protein 4 (α-CTLA-4) could effectively eliminate tumor. However...
    Authors:Kongju Wu, Ming Yi, Shuang Qin, Qian Chu, Xinhua Zheng and Kongming Wu
    Citation:Experimental Hematology & Oncology 2019 8:26
    Content type:Review
     
    Published on: 

  15. The systemic treatment options for advanced gastric cancer (GC) have evolved rapidly in recent years. We have reviewed the recent data of clinical trial incorporating targeted agents, including inhibitors of a...
    Authors:Julie H. Selim, Shagufta Shaheen, Wei-Chun Sheu and Chung-Tsen Hsueh
    Citation:Experimental Hematology & Oncology 2019 8:25
    Content type:Review
     
    Published on: 

  16. Cell-free DNA (cfDNA) next-generation sequencing has the potential to capture tumor heterogeneity and genomic evolution under treatment pressure in a non-invasive manner. Here, we report the detection of EGFR L79...
    Authors:Stephen R. Fairclough, Lesli A. Kiedrowski, Jessica J. Lin, Ori Zelichov, Gabi Tarcic, Thomas E. Stinchcombe, Justin I. Odegaard, Richard B. Lanman, Alice T. Shaw and Rebecca J. Nagy
    Citation:Experimental Hematology & Oncology 2019 8:24
    Content type:Rapid communication
     
    Published on: 

  17. Microvesicles as a new device of cell–cell communication are potentially able to induce some phenotypes and genotypes of an origin cell in a target cell. We evaluate the role of leukemia microvesicles on the l...
    Authors:Farnaz Razmkhah, Sorayya Ghasemi, Masoud Soleimani and Sedigheh Amini Kafi-abad
    Citation:Experimental Hematology & Oncology 2019 8:23
    Content type:Letter to the Editor
     
    Published on: 

  18. The use of direct oral anticoagulant in cancer patients is an emerging issue, which seems to be an alternative to low molecular weight heparin. Every year several new drugs are approved as anticancer treatment...
    Authors:Daniele Santini, Fabrizio Citarella, Bruno Vincenzi, Marco Russano, Giuseppe Tonini and Marco Stellato
    Citation:Experimental Hematology & Oncology 2019 8:22
    Content type:Letter to the Editor
     
    Published on: 

  19. The word of hemoglobinopathy is described for an array of disorders that affecting hemoglobin (Hb) functions. Hb is a molecule with 68 kDa molecular weight, serving as oxygen carrying metalloprotein. Hemoglobi...
    Authors:Zahra Mousavi, Zinat Yazdani, Alireza Moradabadi, Fatemeh Hoseinpourkasgari and Gholamhossein Hassanshahi
    Citation:Experimental Hematology & Oncology 2019 8:21
    Content type:Review
     
    Published on: 

  20. Programmed death-1 (PD-1) inhibitors are among the immunotherapies that have revolutionized our approach to treating several cancers. These novel agents act by blocking PD-1 receptor/PD-1 ligand interactions t...
    Authors:Hoda Z. Pourhassan, David Tryon, Brett Schaeffer, Hamid Mirshahidi and John Wong
    Citation:Experimental Hematology & Oncology 2019 8:20
    Content type:Case report
     
    Published on: 

  22. The human concentrative nucleoside transporter 1 (hCNT1) a product of the SLC28A1 gene is one of the three concentrative nucleoside transporters, with a substrate specificity for physiological pyrimidine nucleosi...
    Authors:Chunmei Wang and John K. Buolamwini
    Citation:Experimental Hematology & Oncology 2019 8:18
    Content type:Short report
     
    Published on: 

  23. Large clonal populations of cells bearing PIG-A mutations are the sine qua non of PNH, but the PIG-A mutation itself is insufficient for clonal expansion. The association between PNH and aplastic anemia supports ...
    Authors:Camille Lobry, Ashish Bains, Leah B. Zamechek, Sherif Ibrahim, Iannis Aifantis and David J. Araten
    Citation:Experimental Hematology & Oncology 2019 8:17
    Content type:Research
     
    Published on: 

  24. Therapy for chronic myeloid leukemia (CLL) is going through a major paradigm shift. Combination chemoimmunotherapy regimens have been the frontline therapies for CLL, whereas chlorambucil remained the standard...
    Authors:Delong Liu and Juanjuan Zhao
    Citation:Experimental Hematology & Oncology 2019 8:15
    Content type:Review
     
    Published on: 

  25. The Bruton’s Tyrosine Kinase (BTK)-inhibitor ibrutinib is highly active in mantle cell lymphoma (MCL) but may inhibit response to anti-CD20 antibody as previously shown in CLL models. We investigated how antib...
    Authors:Alexandra Albertsson-Lindblad, Catja Freiburghaus, Mats Jerkeman and Sara Ek
    Citation:Experimental Hematology & Oncology 2019 8:16
    Content type:Short report
     
    Published on: 

  26. Monoclonal antibodies targeting the cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) (e.g., ipilimumab [IPI]) and the programmed cell death-1 (PD1) receptor (e.g., nivolumab [NIVO]) represent significant br...
    Authors:Ravi Potluri, Sandip Ranjan, Hitesh Bhandari, Helen Johnson, Andriy Moshyk and Srividya Kotapati
    Citation:Experimental Hematology & Oncology 2019 8:14
    Content type:Research
     
    Published on: 

  28. Many cases of acute lymphoblastic leukemia (ALL) carry visible acquired chromosomal changes of pathogenetic, diagnostic, and prognostic importance. Nevertheless, from one-fourth to half of newly diagnosed ALL ...
    Authors:Ioannis Panagopoulos, Marta Brunetti, Margrethe Stoltenberg, Rønnaug A. U. Strandabø, Julie Staurseth, Kristin Andersen, Ilyá Kostolomov, Tarjei S. Hveem, Susanne Lorenz, Tove Anita Nystad, Trond Flægstad, Francesca Micci and Sverre Heim
    Citation:Experimental Hematology & Oncology 2019 8:12
    Content type:Case report
     
    Published on: 

  29. Hepatoblastoma is the most common hepatic malignancy in children, accounting for approximately 80% of all childhood liver tumors. KRAS and NRAS, members of the RAS gene family, are closely linked to tumorigenesis...
    Authors:Tianyou Yang, Yang Wen, Jiahao Li, Tianbao Tan, Jiliang Yang, Jing Pan, Chao Hu, Yuxiao Yao, Jiao Zhang, Yijuan Xin, Suhong Li, Huimin Xia, Jing He and Yan Zou
    Citation:Experimental Hematology & Oncology 2019 8:11
    Content type:Research
     
    Published on: 

  30. Myeloproliferative neoplasms (MPN) are heterogeneous diseases that classified by the presence of Philadelphia chromosome into Philadelphia chromosome negative (Ph-neg) and positive (Ph-pos) myeloproliferative ...
    Authors:Alireza Moradabadi, Alireza Farsinejad, Behzad Khansarinejad and Ahamd Fatemi
    Citation:Experimental Hematology & Oncology 2019 8:10
    Content type:Research
     
    Published on: 

  31. Patients with Myelodysplastic Syndromes (MDS) and secondary Acute Myeloid Leukemia (sAML) have a very poor prognosis after failure of hypomethylating agents (HMA). Stem cell transplantation is the only effecti...
    Authors:Stefanie Jilg, Richard T. Hauch, Johanna Kauschinger, Lars Buschhorn, Timo O. Odinius, Veronika Dill, Catharina Müller-Thomas, Tobias Herold, Peter M. Prodinger, Burkhard Schmidt, Dirk Hempel, Florian Bassermann, Christian Peschel, Katharina S. Götze, Ulrike Höckendorf, Torsten Haferlach…
    Citation:Experimental Hematology & Oncology 2019 8:9
    Content type:Rapid communication
     
    Published on: 

  32. Immune checkpoint inhibitors have radically changed the landscape of anti-tumor therapies in several malignancies. However the adverse events associated with immune checkpoint blockade in combination with othe...
    Authors:Julie Charles, Diane Giovannini, Nicolas Terzi, Carole Schwebel, Nathalie Sturm, Dominique Masson, Marie-Thérèse Leccia, Jean-Yves Cahn, Olivier Manches, Claude-Eric Bulabois and Laurence Chaperot
    Citation:Experimental Hematology & Oncology 2019 8:8
    Content type:Case report
     
    Published on: 

  33. Autologous stem-cell transplantation (ASCT) is a common treatment for lymphoma but it has some mortality.
    Authors:Mattias Carlsten, Martin Jädersten, Anna Hellström, Karin Littmann, Christopher M. Melén, Henna Riikka Junlén, Kristina Sonnevi, Per Ljungman, Bo Björkstrand and Björn Engelbrekt Wahlin
    Citation:Experimental Hematology & Oncology 2019 8:7
    Content type:Research
     
    Published on: 

  34. Thyroid dysfunction has not been previously reported in clinical trials of selective fibroblast growth factor receptor (FGFR) inhibitors including AZD4547. Herein, we report a case of worsening hypothyroidism ...
    Authors:Jeffrey Ahn, Justin Moyers, John Wong and Chung-Tsen Hsueh
    Citation:Experimental Hematology & Oncology 2019 8:6
    Content type:Case report
     
    Published on: 

  35. Small cell lung cancer which constitutes about 15% of lung cancers is pathobiologically and clinically distinct from non small cell cancer. Histologically it is characterized by small cells with scant cytoplas...
    Authors:Vaibhav Verma, Geeti Sharma and Abhijai Singh
    Citation:Experimental Hematology & Oncology 2019 8:5
    Content type:Review
     
    Published on: 

  36. The development of hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion (SIADH) is well recognised in multiple myeloma (MM). SIADH, due to either MM or Bortezomib can be hazardous as se...
    Authors:N. O’Connor-Byrne, S. Glavey, R. Tudor, P. Murphy, C. J. Thompson and J. Quinn
    Citation:Experimental Hematology & Oncology 2019 8:4
    Content type:Case report
     
    Published on: 

  37. Cytogenetic abnormalities and mutated genes indicate the role of consolidation therapy with hematopoietic stem cell transplantation (HSCT) or chemotherapy in acute myeloid leukemia (AML). In this study, we con...
    Authors:Pimjai Niparuck, Nittaya Limsuwanachot, Sulada Pukiat, Pichika Chantrathammachart, Budsaba Rerkamnuaychoke, Sutada Magmuang, Sithakom Phusanti, Kochawan Boonyawat, Teeraya Puavilai, Pantep Angchaisuksiri, Artit Ungkanont and Suporn Chuncharunee
    Citation:Experimental Hematology & Oncology 2019 8:3
    Content type:Research
     
    Published on: 

  38. Mantle cell lymphoma is a relatively new recognized hematological malignant disease, comprising of 2.5–6% non-Hodgkin’s lymphomas. The complexity of its clinical presentations (nodular pattern, diffuse pattern...
    Authors:Abdullah Ladha, Jianzhi Zhao, Elliot M. Epner and Jeffrey J. Pu
    Citation:Experimental Hematology & Oncology 2019 8:2
    Content type:Review
     
    Published on: 

  39. Second allogeneic hematopoietic stem cell transplant (HCT) remains as an option for disease relapse after initial HCT.
    Authors:Yun Fan, Andrew S. Artz, Koen van Besien, Wendy Stock, Richard A. Larson, Olatoyosi Odenike, Lucy A. Godley, Justin Kline, John M. Cunningham, James L. LaBelle, Michael R. Bishop and Hongtao Liu
    Citation:Experimental Hematology & Oncology 2019 8:1
    Content type:Research
     
    Published on: 

  40. Senescence, a state of permanent cell cycle arrest, can be induced by DNA damage. This process, which was initially described in fibroblasts, is now recognized to occur in stem cells. It has been well characte...
    Authors:Stephen Capone, Anthony R. Colombo, Benjamin K. Johnson, Tim J. Triche Jr. and Giridharan Ramsingh
    Citation:Experimental Hematology & Oncology 2018 7:32
    Content type:Research
     
    Published on: 

  41. The evolution of molecular studies in myeloproliferative neoplasms (MPN) has enlightened us the understanding of this complex disease consisting of polycythaemia vera (PV), essential thrombocythemia (ET) and p...
    Authors:Yee Yee Yap, Kian Boon Law, Jameela Sathar, Ngee Siang Lau, Ai Sim Goh, Teng Keat Chew, Soo Min Lim, Padmini Menon, Yong Khee Guan, Azlan Bin Husin, Lily Lee Lee Wong, Lee Ping Chew, Sinari Salleh, Kim Yen Goh, Kin Wah Leong, Sen Mui Tan…
    Citation:Experimental Hematology & Oncology 2018 7:31
    Content type:Research
     
    Published on: 

  42. Organoid technology bridges the gap between conventional two-dimensional cell line culture and in vivo models. The near-physiological technology can virtually recapitulates organ development and human diseases...
    Authors:Hanxiao Xu, Ying Jiao, Shuang Qin, Weiheng Zhao, Qian Chu and Kongming Wu
    Citation:Experimental Hematology & Oncology 2018 7:30
    Content type:Review
     
    Published on: 

  43. Refinement of risk-based treatment stratification by minimal residual disease (MRD) at different time points has improved outcomes of childhood acute lymphoblastic leukemia (ALL). In this prospective study we ...
    Authors:Wasil Jastaniah, Naglla Elimam, Khalid Abdalla, Aeshah A. AlAzmi, Aml M. Elgaml, Ahmad Alkassar, Mustafa Daghistani and Sami Felimban
    Citation:Experimental Hematology & Oncology 2018 7:29
    Content type:Research
     
    Published on: 

  44. Immune checkpoint inhibitor induces tumor rejection by activated host immune system. The anti-tumor immune response consists of capture, presentation, recognition of neoantigen, as well as subsequent killing o...
    Authors:Ming Yi, Shuang Qin, Weiheng Zhao, Shengnan Yu, Qian Chu and Kongming Wu
    Citation:Experimental Hematology & Oncology 2018 7:28
    Content type:Review
     
    Published on: 

  45. The monoclonal antibody daratumumab, approved for treating myeloma, targets CD38, a protein on myeloma and also on CD34+ hematopoietic progenitor cells. Because mobilized CD34+ cells are critical for stem cell...
    Authors:Xun Ma, Sandy W. Wong, Ping Zhou, Chakra P. Chaulagain, Parul Doshi, Andreas K. Klein, Kellie Sprague, Adin Kugelmass, Denis Toskic, Melissa Warner, Kenneth B. Miller, Lisa Lee, Cindy Varga and Raymond L. Comenzo
    Citation:Experimental Hematology & Oncology 2018 7:27
    Content type:Research
     
    Published on: 

  46. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy characterized by neoplastic cells that are positive for CD123, CD4, BDCA2, and TCL1 and aberrant expression ...
    Authors:Kamal Chamoun, Sanam Loghavi, Naveen Pemmaraju, Marina Konopleva, Michael Kroll, Madeleine Nguyen-Cao, Marisa Hornbaker, Courtney D. DiNardo, Tapan Kadia, Jeffrey Jorgensen, Michael Andreeff, Shimin Hu and Christopher B. Benton
    Citation:Experimental Hematology & Oncology 2018 7:26
    Content type:Case report
     
    Published on: 

  47. Immunotherapeutic protocols have focused on identification of stimuli that induce effective anti-leukemic immune responses. One potent immune stimulus is the encounter with allogeneic cells. Our group previous...
    Authors:Alejandro Pando, John L. Reagan, Martha Nevola and Loren D. Fast
    Citation:Experimental Hematology & Oncology 2018 7:25
    Content type:Short report
     
    Published on: 
Publicado por en

No hay comentarios:

Publicar un comentario

Suscribirse a: Enviar comentarios (Atom)